ACE
MOLECULAR TARGETangiotensin I converting enzyme
ACE (angiotensin I converting enzyme) is targeted by 12 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting ACE
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | telmisartan | 4.29 | 72 |
| 2 | Lisinopril | 2.77 | 15 |
| 3 | Enalapril | 2.48 | 11 |
| 4 | omapatrilat | 2.30 | 9 |
| 5 | valyltryptophan | 2.20 | 8 |
| 6 | mdl 28170 | 2.08 | 7 |
| 7 | ore 1001 | 1.79 | 5 |
| 8 | Thiorphan | 1.61 | 4 |
| 9 | Fosinopril | 1.10 | 2 |
| 10 | Losartan | 0.69 | 1 |
| 11 | Bradykinin | 0.69 | 1 |
| 12 | Vorinostat | 0.69 | 1 |
About ACE as a Drug Target
ACE (angiotensin I converting enzyme) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 12 compounds with documented ACE interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
ACE inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.